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Pharmacogenetics of oral antidiabetes drugs: evidence for
diverse signals at the IRS1 locus
S Prudente1, R Di Paola2, S Pezzilli1,3, M Garofolo4, O Lamacchia5, T Filardi3, GC Mannino6, L Mercuri1, F Alberico1, MG Scarale2,7,
G Sesti6, S Morano3, G Penno4, M Cignarelli5, M Copetti7 and V Trischitta1,2,3
To investigate the role of IRS1 locus on failure to oral antidiabetes drugs (OADs) we genotyped single-nucleotide polymorphisms
(SNPs), rs2943641, rs7578326 (tagging all SNPs genome-wide associated with type 2 diabetes (T2D) and related traits at this locus)
and rs1801278 (that is, the loss-of-function IRS1 G972R amino acid substitution) in 2662 patients with T2D. Although no association
with OAD failure was observed for rs2943641 and rs7578326 SNPs (odds ratio (OR): 1.04, 95% confidence interval (CI): 0.93–1.16 and
OR: 0.97, 95% CI: 0.87–1.09 respectively), a significant association was observed for rs1801278 (OR: 1.34, 95% CI: 1.08–1.66). When
meta-analyzed with previous published data, an allelic OR of 1.41 (1.15–1.72; P= 0.001) was obtained, so that homozygous R972R
individuals have480% higher risk of failing to OADs as compared with their G972G counterparts. In all, though further studies are
needed for confirming this finding, our present data point to IRS1 rs1801278 as a potential biomarker for pursuing the goal of
stratified medicine in the field of antihyperglycemic treatment in T2D.
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INTRODUCTION
Type 2 diabetes (T2D) increases the risk of end-stage renal disease,
blindness, major adverse cardiovascular events and, eventually,
all-cause mortality.1 All this imposes a severe burden on patients
and their relatives as well as on health-care systems; a burden that
is likely to increase over the next decades because of the epidemic
proportion that T2D is taking on.2
Reducing blood glucose plays a critical role for preventing and
minimizing the devastating consequences of T2D. Several options
are available for treating hyperglycemia, among which oral
antidiabetes drugs (OADs) are the most common.
As an average, OADs are reasonably effective; however, when
looking at individual level, they achieve adequate glycemic control
in approximately only half of patients with T2D.3 In addition, OADs
may cause significant adverse effects,4,5 and hence it happens that
there are diabetic individuals on OADs who pay the cost of
suffering of clinically relevant side effects without even benefiting
adequately in terms of blood glucose lowering. This is to say that a
more precise way (that is, stratified medicine) of using OADs in
each single diabetic patient is definitively needed.3,6
Studies on the pharmacogenetics of OADs have pointed,
among others, genes that play a role on the pathogenic mecha-
nisms of hyperglycemia.7 Among these, we have recently reported
that IRS1 rs1801278 single-nucleotide polymorphism (SNP) is
associated with OAD response in patients with T2D.8 Of note,
rs1801278 encodes for a loss-of-function G972R amino acid
substitution, as repeatedly reported by in vitro,9,10 animal11 and
in vivo12,13 studies.
Other common variants at the IRS1 locus, which are very
relevant in the context of T2D and related traits14–22 and which are
not in linkage disequilibrium (LD) with rs1801278, were not
investigated in our first study, thus leaving inconclusive our
understanding about the role of IRS1 locus on OAD efficacy.
In this new study, we have verified whether information derived
from all SNPs in the IRS1 locus so far associated at genome-wide
level of significance with T2D and related traits14–22 are also
associated with efficacy of OADs, as mainly represented by
metformin–sulfonylureas combination. This aim has been pursued
by genotyping SNPs rs2943641 and rs7578326 (as Tag SNPs of the
6 SNPs in the IRS1 locus associated with T2D and related traits) in
a case–control study comprising a total of 2662 patients with T2D
in whom the initiation of insulin therapy in those already on OADs
was considered as a proxy of inefficacy of these agents.
MATERIALS AND METHODS
Study samples
Five independent samples of patients from Italy with T2D (defined
according to American Diabetes Association 2003 criteria), whose general
clinical features are shown in Table 1, were studied. The five samples were
recruited in outpatient diabetic clinics at four different research/academic
hospitals from central southern Italy. Briefly, the first two cohorts of
patients (that is, SGR1 and SGR2) were recruited at Scientific Institute Casa
Sollievo della Sofferenza, San Giovanni Rotondo (Apulia) between
November 2000 and September 2005 and between September 2008 and
October 2010.23 Patients of the third cohort (that is, Foggia) were
consecutively recruited at the Endocrine Unit of the University of Foggia
(Apulia) from January 2002 to September 2008.8 Patients of the fourth
cohort (that is, Pisa) were consecutively recruited between November 2002
and April 2004 at the University Hospital of Pisa (Tuscany).8 Finally, patients
of the last cohort (that is, Rome) were consecutively recruited between
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2005 and 2012 at the ‘Sapienza’ University Hospital of Rome.24 From this
cohort only 255 DNA samples were available for the present study.
The study protocol was approved by local institutional review boards
and was conducted according to the Helsinki Declaration. Written
informed consent was obtained from each participant.
All patients underwent physical examination and measurements of
glycated hemoglobin (HbA1c), lipid levels, blood pressure and body mass
index as previously described.23,24
Presence of hypertension was defined as a systolic blood pressure of
4140 mm Hg or diastolic blood pressure of 490 mm Hg or both, or the
presence of antihypertensive treatment.
Status ascertainment
In all samples, ‘cases’ (a total of 1267 individuals) were patients requiring
insulin therapy added either on or instead of maximal or near-maximal
doses of OADs (mostly sulfonylureas and metformin, with only 2–4% also
being on thiazolidinediones and/or gliptins at the time of recruitment) due
to uncontrolled diabetes (that is, HbA1c 48%), in the absence of known
conditions predisposing to poor glycemic control (that is, endocrine and
infectious diseases, cancers, and glucocorticoid treatment) (Table 1).
Conversely, ‘controls’ (a total of 1397 individuals) were all patients who
were in acceptable glycemic control (that is, HbA1c ⩽ 8%) in the absence
of insulin therapy (Table 1). All patients had no clinical signs of
autoimmune diseases.
Tag SNP selection and genotyping
Six SNPs in the IRS1 locus have been so far reported associated at
genome-wide level of significance with T2D and other cardiometabolic
traits (including rs7578326, rs2943634, rs2943640, rs2943641, rs2972146
and rs2943650).14–22 The extent of LD among these six SNPs and among
these six SNPs and rs1801278 (that is, IRS1 G972R) was evaluated by
Haploview25 based on data from phase 2 of the HapMap (CEU sample).
Although all six SNPs were in high LD, two tag SNPs to be further
investigated were selected by Tagger.26
DNA was extracted from whole blood using standard methods. All study
participants were genotyped for Tag SNPs rs2943641 and rs7578326 by
means of ready to use TaqMan assays (Life Technologies) on a HT 7900
platform (Applied Biosystems, Foster City, CA, USA). Genotyping quality
was tested by including six blinded duplicate samples in each 384-well
assay. The average agreement rate of duplicate samples was 499%. All
samples were in Hardy–Weinberg equilibrium (HWE) (P40.05).
Genotype data for the rs1801278 SNP were already available for 4 out of
5 samples (that is, SGR1, SGR2, Pisa and Foggia),8 and hence only samples
from Rome were genotyped at this SNP, as described above.
Statistical methods
Patients’ baseline characteristics were reported as mean± s.d. and
percentages for continuous and categorical variables, respectively. Log
transformation was used when analyzing disease duration that was non-
normally distributed. Deviation from HWE of the rs1801278, rs2943641 and
rs7578326 was investigated by exact χ2 test.
Univariate or multivariable logistic regression analysis was used to assess
the effect of the IRS1 SNPs (assuming an additive genetic model of
inheritance) on dichotomous outcomes in the pooled sample in a fixed-
effects individual participant data meta-analysis manner27 (adjusting for
study sample after having observed no SNP-by-study sample interaction).
Results were reported as odds ratios (ORs) with 95% confidence
intervals (CIs).
Aggregate data meta-analysis was also performed to combine our
results with those previously reported.28 Between-study heterogeneity was
assessed by Cochran’s Q test. In the absence of heterogeneity (P40.10),
fixed-effects meta-analysis was used to estimate summary OR and the
corresponding 95% CI.
A P-value of o0.05 was considered as statistically significant.
All analyses were performed using SPSS version 15.0 (Chicago, IL, USA)
and Comprehensive Meta-analysis Software (Biostat, Inc.).
Power study
In the 5 pooled samples, we had 499% power with a type I error of
5% to detect an OR equal to 1.37 (as reported for G972R)8 for both
rs2943641 (minor allele frequency= 0.368) and rs7578326 (minor allele
frequency= 0.362).
RESULTS
Clinical features of all study subjects from 5 independent samples
(that is, 2664 individuals) are shown in Table 1. Not surprisingly,
many of such features were different between controls and
cases, pointing to a more severe disease in the latter individuals
(Table 1).
LD extent evaluated across the 6 SNPs previously associated at
genome-wide level of significance to T2D and cardiometabolic
traits14–22 shows that all SNPs are in high LD (r2 40.9)
(Supplementary Figure 1). Two tag SNPs (that is, rs2943641 and
rs7578326) were able to capture the entire genetic variability of all
the 6 SNPs, whereas none of them were in LD with rs1801278 SNP
(that is, IRS1 G972R), with D’ and r2 values for each SNP being
⩽ 0.65 and ⩽ 0.02, respectively.
Association between SNP rs2943641 and failure to OADs
Genotype frequencies at rs2943641, available in 1391 controls and
1211 cases, were in HWE in all samples (all P-values being40.05).
Genotype distribution across controls and cases as well as the
additive OR (95% CI) for failure to OADs in each single sample are
shown in Figure 1a. As no SNP-by-sample heterogeneity on failure
to OADs was observed (Phet = 0.50), data from all samples were
pooled and analyzed. No association was observed between
rs2943641 and failure to OADs in each single sample and in the
pooled sample as well (Figure 1a).
No association was observed between rs2943641 and any
clinical feature in controls and cases from each single sample
Table 1. Clinical features of patients with T2D from five independent study samples
Foggia Pisa SGR1 SGR2 Rome
Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases
N 166 236 511 267 287 422 252 268 181 74
Male (n (%)) 91 (54.8) 108 (45.2) 321 (62.8) 138 (51.7) 156 (54.4) 196 (46.4) 141 (56.0) 157 (58.6) 125 (69.1) 47 (63.5)
Age (years) 63.4± 12.5 64.6± 10.0 59.5± 7.2 58.7± 8.2 60.6± 9.9 64.3± 9.2 62.1± 8.7 63.0± 9.5 66.2± 8.4 65.4± 9.1
BMI (kg m− 2) 30.0± 6.4 30.2± 6.2 29.6± 5.3 29.1± 5.2 30.9± 5.5 30.8± 6.0 30.6± 6.1 31.0± 6.2 28.5± 4.1 28.5± 5.2
Duration of diabetes (years) 9.3± 8.8 16.9± 10.0 7.4± 6.9 16.4± 10.2 6.4± 6.7 15.5± 9.2 6.7± 6.8 15.9± 9.0 8.8± 8.5 17.4± 10.5
HBA1C (%) 6.7± 0.8 9.5± 2.0 6.9± 0.7 8.3± 1.2 6.8± 0.7 9.3± 1.9 6.8± 0.7 8.9± 2.0 6.4± 0.7 8.0± 1.4
Antihypertensive therapy
(n (%))
121 (73.3) 190 (80.9) 280 (54.8) 136 (50.9) 147 (54.9) 255 (66.9) 186 (74.1) 213 (79.8) 138 (76.2) 58 (78.4)
Statin therapy (n (%)) 45 (27.3) 109 (46.4) 129 (25.2) 77 (28.8) 74 (25.8) 160 (37.9) 178 (70.6) 190 (70.9) 106 (58.6) 48 (64.9)
Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; SGR, San Giovanni Rotondo; T2D, type 2 diabetes. BMI values are mean± s.d.
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(data not shown) as well as in the pooled one (Supplementary
Table 1).
Association between SNP rs7578326 and failure to OADs
Genotype frequencies at rs7578326, available in 1394 controls and
1180 cases, were in HWE in all samples (all P-values being40.05).
Genotype distribution across controls and cases as well as the
additive OR (95% CI) for failure to OADs in each single sample are
shown in Figure 1b. As no SNP-by-sample heterogeneity on failure
to OADs was observed (Phet = 0.31), data from all samples were
pooled and analyzed. No association was observed between
rs7578326 and failure to OADs in each single sample and in the
pooled sample as well (Figure 1b).
No association was observed between rs7578326 and any
clinical feature in each single sample (data not shown) as well as in
the pooled one (Supplementary Table 2).
Association between SNP rs1801278 and failure to OADs
Genotype frequencies at rs1801278 (that is, IRS1 G972R) now
evaluated in a total of 1396 controls and 1266 cases were in HWE
in all samples (all P-values being 40.05).
Genotype distribution across controls and cases as well as the
additive OR (95% CI) for failure to OADs in each single sample are
shown in Figure 1c. As no SNP-by-sample heterogeneity on failure
to OADs was observed (Phet = 0.45), data from all samples were
pooled and analyzed (Figure 1c). Individuals carrying the minor
allele at rs1801278 (that is, carrying the IRS1 R972 variant) tended
to be more frequent among cases in all samples, and hence in the
pooled sample they had 34% significantly higher risk of being
cases (P= 0.008).
No association was observed between rs1801278 and any
clinical feature in each single sample (data not shown) as well as in
the pooled one (Supplementary Table 3).
Figure 1. Meta-analysis of five case–control studies. The cumulative effect of the five studies on the association between rs2943641 (a),
rs7578326 (b) and rs1801278 (c) polymorphisms and the failure to oral antidiabetes drugs (OADs) was tested by a fixed-effects model. Odds
ratios (ORs) and 95% confidence intervals (Cis) for additive genetic model are shown. Sizes of OR symbols are proportional to the study
sample size. SGR, San Giovanni Rotondo.
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When our present data were meta-analyzed with those
previously obtained in an independent study,28 an additive OR
equal to 1.41 (1.15–1.72; P= 0.001) was obtained.
The association between rs1801278 (that is, IRS1 G972R) and
failure to OADs remained significant after adjusting for rs2943641
or for rs7578326 (P= 0.028 and P= 0.037, respectively), whereas an
∼ 50% reduction on a log scale was observed after adjusting for
disease duration (OR becoming 1.17, P= 0.19).
In order to exclude that our findings were influenced by the
status ascertainment we used, a sensitivity analysis was carried out
in the pooled sample by excluding from controls all individuals
who were treated with only diet (n= 292), and from cases all
individuals with HbA1c o8% on insulin treatment (n= 505). In the
remaining individuals the results obtained for all three SNPs
were not different than that observed in the whole sample
(Supplementary Table 4).
DISCUSSION
In a pooled analysis, comprising a total of 2662 diabetic
individuals from central southern Italy, we report for the first
time that rs2943641 and rs7578326, which are Tag SNPs of all
other SNPs in the IRS1 locus so far associated with T2D and cardio-
metabolic traits,14–22 are not associated with failure to OADs.
Conversely, our present data confirm and reinforce previous
evidence for the association between SNP rs1801278 (IRS1 G972R)
and failure to OADs.8 When present data are meta-analyzed with
those previously reported by one of us,28 an overall 40% increased
risk of OAD failure is observed for carriers of the IRS1 R972 variant,
with a statistical significance that, though not formally excluding a
false positive finding, becomes robustly credible. The credibility of
our present finding on rs1801278 is also strengthened by all study
samples showing a homogeneous trend of association toward the
same direction (Figure 1c).
Data on all three SNPs investigated in this study add new
insights into the role of the IRS1 locus on the risk of failure to
OADs. In fact, although rs2943641 and rs7578326 are established
markers of T2D,16,19 the role of rs1801278 (IRS1 G972R) is at
issue,29 thus making unlikely that the association between this
latter SNP and failure to OADs is mainly mediated by direct effects
on glucose homeostasis. Rather, it becomes reasonable that the
observed association with reduced responsiveness to OADs is
secondary to yet unknown effects of the loss-of-function IRS1 R972
variant on specific mechanism(s) of action of OADs. As a matter of
fact, the IRS1 R972 variant has been reported to affect in vivo
both insulin sensitivity12,13 and secretion30,31 that are specifically
targeted by metformin and sulfonylureas,3 by far the most utilized
OAD in our study. It can therefore be hypothesized that in a
condition in which insulin sensitivity and/or secretion are
genetically impaired, as in carriers of the IRS1 R972 variant,
metformin and sulfonylureas are less active, thus increasing the
chance of a clinically manifest OAD failure.
Conversely, as the IRS1 R972 is involved in anticipating disease
onset,29 it cannot be excluded that carriers of this variant are at
higher risk of ODA failure because of being affected by diabetes
of longer duration and, consequently, higher severity. That this
can be, at least partly, the case is suggested by the obser-
vation that when diabetes duration is used as a covariate, the OR
of OAD failure in IRS1 R972 decreases from 1.34 to 1.17,
representing an almost 50% reduction on a log scale. This may
be considered a general phenomenon regarding failures to any
treatment to T2D, as well as any progressive disease in which
severity increases over time. In the context of T2D, failing to
antihyperglycemic therapies rather than being caused by a drug-
specific defective molecular mechanisms may be because of
progressive deterioration of insulin secretion and sensitivity,3 that
are likely to affect treatment efficacies, regardless of their
mechanisms of action.
We do acknowledge that cross-sectional study design and
ascertainment strategy, based on the addition of insulin therapy
for defining failure to OADs, can be viewed as a limitation of
our study. Having admitted so, it is of note that a sensitivity
analysis was carried out for addressing this subject, with no much
change observed on the association with OAD failure for any of
the three SNPs of interest. Hence, although we cannot
exclude that in some patients adding insulin may have been
secondary to metformin-related gastrointestinal symptoms and/or
sulfonylureas-dependent recurrent hypoglycemic episodes, rather
than OAD failure, it is unlikely that such possible incorrectness in
status ascertainment has biased our results.
We also acknowledge that most of our patients were on a
combination of metformin and sulfonylureas, thus making
impossible obtaining information on the role of IRS1 variability
on the efficacy of each oral agent, as singly considered.
The strength of our study is the ethnic and geographical
homogeneity across samples (all being from central southern
Italy); it would be of interest to understand whether similar results
can be obtained in samples characterized by different environ-
mental and/or genetic background.
In conclusion, among the three SNPs at the IRS1 locus that we
investigated in the present study, only rs1801278 (IRS1 G972R) is
robustly associated with OAD failure in terms of both statistical
significance and clinical effect size, with homozygous R972R
individuals having an 80% higher risk of needing insulin addition
on top of, or instead of, previous OAD as compared with their
homozygous G972G counterparts.
Though the biology underlying this association is elusive and
need to be addressed more deeply, such a high clinical impact
points to rs1801278 (IRS1 G972R) as a potential biomarker for
pursuing the goal of stratified medicine in the field of
antihyperglycemic treatment in T2D.
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